Clinical Trials Logo

Coronary Arteriosclerosis clinical trials

View clinical trials related to Coronary Arteriosclerosis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05695547 Not yet recruiting - Clinical trials for Coronary Arteriosclerosis

VR Education in Patients Undergoing Coronary Angiography

Start date: January 25, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to compare standard education with VR augmented education in patients undergoing selective coronary angiography.

NCT ID: NCT04321473 Not yet recruiting - Clinical trials for Coronary Arteriosclerosis

Registry on Left Main Coronary Artery Bifurcation Percutaneous Intervention

WE REMAIN EBC
Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

The slowly accruing evidence on the treatment of patients with left main coronary artery (LMCA) disease drove evolution in guidelines, that currently establish equivalent safety and efficacy for percutaneous coronary intervention (PCI) as compared to surgery, with a class of recommendation that is subjected to the extension and complexity of concomitant coronary artery disease, as assessed by the SYNTAX score. The severity of LMCA disease, although extremely relevant due to the extent of the supplied myocardium, is often difficult to assess with traditional angiography, due to lack of appropriate angiographic views, absence of a true "reference" segment, interaction with the intubating catheter. Intravascular techniques with either imaging or functional assessment have been variously tested, although with a disturbing rate of discordant results; moreover, they are frequently underused for a number of reasons, including the additional time needed to assess both left anterior descending (LAD) and left circumflex (LCx) arteries, technical challenges, costs and the small risk associated with maneuvering such devices. Fractional flow reserve (FFR) measured from the coronary angiogram (FFRangio) alone recently documented a high diagnostic accuracy compared with pressure-wire derived FFR. As for the anatomical localization, the majority of LMCA lesions occur at the bifurcation, where PCI results are less favourable. The distal LMCA differs from the other bifurcations in several characteristics: a) a notable mismatch between the LMCA and the left anterior descending (LAD) artery, hampering the selection of an adequately sized stent, b) the presence of a trifurcation, with a large ramus arising from LMCA in about 10% of cases, c) the presence of left or co-dominant circulation, with the LMCA supplying all or nearly all left ventricular myocardium in about 15% of cases. Therefore, although the European Bifurcation Club (EBC) recommends a provisional side branch approach in most cases of distal LMCA disease, the threshold for placing a second stent in the side branch may be lower in lesions located on LM bifurcation compared with non-LMCA bifurcations. As for double stenting, the evidence is controversial and a consensus is lacking. Moreover, the optimal treatment of patients with LM trifurcations is still undefined. The aim of this study is therefore to determine the optimal strategy for the treatment of LM bifurcated lesions.

NCT ID: NCT00117936 Not yet recruiting - Coronary Disease Clinical Trials

Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

Start date: March 2020
Phase: Phase 2
Study type: Interventional

Treatment for no-option heart patients with coronary artery disease. Procedure includes the injection into the heart of a protein growth factor, administered by the Biological Delivery Systems MyoStar injection and mapping catheters, to stimulate the growth of blood vessels around blocked coronary arteries.